课题基金 / 基金详情

A Shimadzu micro-scale HPLC system for analysis of nanobody repertoires

A Shimadzu micro-scale HPLC system for analysis of nanobody repertoires
用于分析纳米抗体库的岛津微型 HPLC 系统
批准号:
10794691
负责人:
Yi Shi
金额:
$8.68万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-09-10 至 2025-08-31

项目摘要

项目成果

Yi Shi的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结/摘要 骆驼VHH抗体或纳米抗体是用于生物医学应用的引人注目的新型抗体。 纳米抗体的特征在于小尺寸、稳健折叠和高稳定性。尽管它们的体积很小, 在单体结合中,它们保留了对抗原结合的高亲和力和选择性。此外,纳米抗体可以是 易于从微生物中以低成本生产。它们是生物工程的理想模块蛋白, 显示出在促进疾病诊断和治疗方面的有希望的潜力。 在这里,我们建议开发综合技术,以促进纳米抗体的发现和表征。在 与此同时,我们将应用我们的方法和工具纳米抗体,使生物医学发现和治疗。在 在此补充申请中,我们申请资金以获得灵敏的HPLC装置(Shimazu HPLC Nexera 40) 支持我们提出的与纳米抗体鉴定和生物物理,结构和功能相关的科学 特征化。
英文摘要
PROJECT SUMMARY/ABSTRACT Camelid VHH antibodies or Nanobodies are a compelling new class of antibodies for biomedical applications. Nanobodies are characterized by small size, robust fold, and high stability. Despite their small size and monomeric binding, they retain high affinity and selectivity for antigen binding. In addition, nanobodies can be readily produced with low cost from microbes. They are ideal modular proteins for bioengineering and have shown promising potential in facilitating disease diagnosis and therapy. Here we propose to develop integrative technologies to facilitate nanobody discovery and characterization. In parallel, we will apply our methods and tool nanobodies to enable biomedical discoveries and therapeutics. In this supplement application, we request funds to obtain a sensitive HPLC device (Shimazu HPLC Nexera 40) to support our proposed science related to nanobody identification and biophysical, structural and functional characterizations.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1126/sciadv.abh0319
发表时间: 2021-05
期刊: Science advances
影响因子: 13.6
作者: [Nambulli S, Xiang Y, Tilston-Lunel NL, Rennick LJ, Sang Z, Klimstra WB, Reed DS, Crossland NA, Shi Y, Duprex WP]
通讯作者: Duprex WP
Development of the next generation antibody technologies and their applications
Development of the next generation antibody technologies and their applications
Development of the next generation antibody technologies and their applications
海外基金